303 related articles for article (PubMed ID: 32820849)
1. Erythrodermic pityriasis rubra pilaris treatment: Two case reports and literature review.
Camela E; Miano C; Di Caterino P; Lo Presti M; De Fata Salvatores G; Fabbrocini G; Megna M
Dermatol Ther; 2020 Nov; 33(6):e14223. PubMed ID: 32820849
[TBL] [Abstract][Full Text] [Related]
2. A case of resistant pityriasis ribra pilaris responsive to combination acitrentin and ustekinumab.
Cook E; Tran KW; Kollipara S; Tarbox M; Akin R
Dermatol Online J; 2020 Mar; 26(3):. PubMed ID: 32609453
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of a child's pityriasis rubra pilaris (PRP) with ustekinumab and acitretin.
Katharina M; Sylvia S; Matthias B; Ulrich M; Martin L
Pediatr Dermatol; 2022 Jul; 39(4):659-661. PubMed ID: 35859269
[TBL] [Abstract][Full Text] [Related]
4. Successful response of refractory type I adult-onset pityriasis rubra pilaris with ustekinumab and acitretin combination therapy.
Byekova Y; Sami N
J Dermatol; 2015 Aug; 42(8):830-1. PubMed ID: 25982628
[No Abstract] [Full Text] [Related]
5. Methotrexate treatment in a case of juvenile pityriasis rubra pilaris.
Boyd AH; Polcari IC
Pediatr Dermatol; 2018 Jan; 35(1):e62-e63. PubMed ID: 29044698
[TBL] [Abstract][Full Text] [Related]
6. Treatment of pityriasis rubra pilaris: a case series of 28 patients.
Kromer C; Lippert U; Schön MP; Mössner R
Eur J Dermatol; 2020 Oct; 30(5):569-579. PubMed ID: 33021474
[TBL] [Abstract][Full Text] [Related]
7. Refractory pityriasis rubra pilaris treated with etanercept, adalimumab, or ustekinumab: A retrospective investigation.
Maloney NJ; Hisaw LD; Worswick S
Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 29034547
[TBL] [Abstract][Full Text] [Related]
8. Ustekinumab treatment of pityriasis rubra pilaris: A report of five cases.
Napolitano M; Lembo L; Fania L; Abeni D; Didona D; Didona B
J Dermatol; 2018 Feb; 45(2):202-206. PubMed ID: 29080273
[TBL] [Abstract][Full Text] [Related]
9. Systemic therapies of pityriasis rubra pilaris: a systematic review.
Kromer C; Sabat R; Celis D; Mössner R
J Dtsch Dermatol Ges; 2019 Mar; 17(3):243-259. PubMed ID: 30520557
[TBL] [Abstract][Full Text] [Related]
10. Acute juvenile pityriasis rubra pilaris: a case report after mononucleosis infection.
Betto P; Vassilopoulou A; Colombari R; Veller-Fornasa C
G Ital Dermatol Venereol; 2008 Aug; 143(4):271-3. PubMed ID: 18833084
[TBL] [Abstract][Full Text] [Related]
11. Treatment of pityriasis rubra pilaris type I: a systematic review.
Engelmann C; Elsner P; Miguel D
Eur J Dermatol; 2019 Oct; 29(5):524-537. PubMed ID: 31789274
[TBL] [Abstract][Full Text] [Related]
12. Biologics for Treatment of Pityriasis Rubra Pilaris: A Literature Review.
Chandy RJ; Chokshi A; Tan I; Feldman SR
J Cutan Med Surg; 2024; 28(3):269-275. PubMed ID: 38549359
[TBL] [Abstract][Full Text] [Related]
13. Late onset pityriasis rubra pilaris type IV treated with low-dose acitretin.
Mota F; Carvalho S; Sanches M; Selores M
Acta Dermatovenerol Alp Pannonica Adriat; 2016; 25(1):15-7. PubMed ID: 27014774
[TBL] [Abstract][Full Text] [Related]
14. Pityriasis rubra pilaris (type I) following administration of the BNT162b2 mRNA COVID-19 vaccine: Successful treatment with ustekinumab and acitretin.
Gamonal SBL; Marques NCV; Pereira HMB; Gamonal ACC
Dermatol Ther; 2022 Dec; 35(12):e15899. PubMed ID: 36196603
[No Abstract] [Full Text] [Related]
15. Recurrent Pityriasis Rubra Pilaris: A Case Report.
MacGillivray ME; Fiorillo L
J Cutan Med Surg; 2018; 22(6):624-626. PubMed ID: 29754526
[TBL] [Abstract][Full Text] [Related]
16. Treatment of pityriasis rubra pilaris with pimecrolimus cream 1%.
Gregoriou S; Argyriou G; Christofidou E; Vranou A; Rigopoulos D
J Drugs Dermatol; 2007 Mar; 6(3):340-2. PubMed ID: 17373199
[TBL] [Abstract][Full Text] [Related]
17. Erythrodermic pityriasis rubra pilaris managed at home: intensive community care followed by ustekinumab.
Ismail N; Callander J; Williams M; Anstey AV
Clin Exp Dermatol; 2018 Aug; 43(6):749-751. PubMed ID: 29779249
[No Abstract] [Full Text] [Related]
18. Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris.
Di Stefani A; Galluzzo M; Talamonti M; Chiricozzi A; Costanzo A; Chimenti S
J Dermatol Case Rep; 2013 Mar; 7(1):5-9. PubMed ID: 23580907
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effect of ustekinumab in familial pityriasis rubra pilaris with a new missense mutation in CARD14.
Lwin SM; Hsu CK; Liu L; Huang HY; Levell NJ; McGrath JA
Br J Dermatol; 2018 Apr; 178(4):969-972. PubMed ID: 28301045
[TBL] [Abstract][Full Text] [Related]
20. CARD14-associated papulosquamous eruption (CAPE) in a toddler responding to treatment with acitretin.
Wong GHZ; Chia SY; Wei H; Rafi'ee K; Koh MJA; Tan EC
Pediatr Dermatol; 2021 Jul; 38(4):970-972. PubMed ID: 34075616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
